loanranger
5 days ago
As you quoted "On June 9, 2022, Innovation Pharmaceuticals Inc. (the “Company”) entered into a Series A Preferred Share Purchase Agreement (the “Purchase Agreement”) with Squalus Med Ltd., a company established under the laws of the State of Israel (“SML”), pursuant to which the Company purchased 55,556 shares of SML’s Series A Redeemable Preferred Shares (the “Series A Shares”)"....
....and it is those shares that are now useless to IPIX. They can't sell them, lend them or use them as security. Hence they are currently worthless to IPIX.
Shareholders of the Company need to know that.
MackG
6 days ago
IPIX purchased and still owns a substantial interest in BeaMed according to a prior IPIX announcement in 2022:
INNOVATION PHARMACEUTICALS, INC. BOUGHT 41.6 % OF SQUALUS MED, LTD. (NOW BT BeaMed Technologies)
IPIX has bought a sizable stake in an Israeli company that has a novel laser ablation technology, Squalus Medical, Ltd. (now, BT BeaMed Technologies.
Per new 8k- Item 1.01 Entry into a Material Definitive Agreement.
On June 9, 2022, Innovation Pharmaceuticals Inc. (the “Company”) entered into a Series A Preferred Share Purchase Agreement (the “Purchase Agreement”) with Squalus Med Ltd., a company established under the laws of the State of Israel (“SML”), pursuant to which the Company purchased 55,556 shares of SML’s Series A Redeemable Preferred Shares (the “Series A Shares”) and a warrant (the “Warrant”) to purchase 27,778 Series A Shares for aggregate consideration of $4,000,000, or approximately $72.00 per Series A Share. Following the closing under the Purchase Agreement, the Company owns approximately 35.7% of SML’s issued and outstanding equity securities and approximately 41.6% of SML’s equity securities on a fully diluted basis. The Company also entered into customary investor rights and indemnification agreements with SML." IMO, There is every reason to believe based on news of recent BeaMed hires that things are moving forward with the amazing StingRay Laser System.
loanranger
1 week ago
"The catalyst will likely be the first product with Brilacidin that IPIX gets a FDA nod for after a successful Phase 3. "
There are no Phase 3s under way nor is the Company in a position to undertake any.
"IPIX is currently in a holding pattern because its finances are dependent on its investment in BeaMed."
Cummings has been granted an equitable lien and continuing security interest in IPIX's investment in BeaMed. IPIX's investment in BeaMed is worthless to IPIX at the moment per the Order of Postjudgment Security in Case no. 2077CV00101.
"08/23/2024 ORDER: of Post Judgment Security
..II. ALTERNATIVE SECURITY
In accordance with General Laws c. 223, sec. 86A, Innovation shall obtain and provide within thirty (30) days of this Order a bond payment to Cummings with sureties to be approved by this Court conditioned to pay Cummings the amount of at least $1,375,811.36, within thirty (30) days of the date when execution may issue upon judgment, which bond shall be filed with the clerk after its approval by the Court. "
Most recent appeals case (2024-P-0638) activity:
11/12/2024 #18 Appellee brief filed for Cummings Properties, LLC by Attorney Michael Barker.
11/26/2024 #19 Motion of Appellant to extend date for filing Reply Brief filed for Innovation Pharmaceuticals Inc. by Attorney Daniel Dwyer.
11/26/2024 RE#19: Allowed to 1/19/25. *Notice.
No mention has been made in either docket of the provision of the bond to Cummings. I think it's obvious that IPIX couldn't fund it.
TheHound
2 weeks ago
The Great Cannoli Caper: A Tale of IPIX Deception
In Paris streets where croissants gleam,
A curious plot began to scheme.
Not in Naples, not in Rome,
But under the Eiffel’s iron dome.
A pastry chef with toque held high,
Declared, beneath a sugared sky:
“Who needs ricotta, shells, or cream?
We’ll build a better cannoli dream!”
But oh, mon Dieu, the plan was flawed,
For what emerged was pastry fraud.
No golden shells, no creamy core,
Just hollow lies and marketing lore.
Then came IPIX, slick and sly,
With polished suits and eager eye.
“Fear not, mes amis, don’t despair!
We’ll sell these treats—beyond compare!”
Posters plastered, ads unfurled,
“The best cannolis in the world!”
But one brave gourmand took a bite,
And gasped in horror at the sight.
“Where’s the ricotta? Where’s the flair?
This shell’s as empty as the air!”
The crowd erupted, truth laid bare,
IPIX caught in their éclairs.
But profits soared, despite the sham,
As tourists bought each pastry scam.
For in the city where dreams are sold,
A fake cannoli still looks gold.
So here’s a lesson, sweet but stern:
Authenticity’s hard to earn.
Whether Paris skies or Sicilian sun,
A real cannoli fools no one. End the French fraud. Take the gun leave the cannolis.